K. Gorden

发表

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts

Amanda R. Campbell, F. Lund-Johansen, Yair Benita, 2016, Journal for ImmunoTherapy of Cancer.

Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod.

R. Noelle, P. Fitzgerald-Bocarsly, Richard L. Miller, 2002, Cellular immunology.

Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity

Bali Pulendran, Shizuo Akira, Sefik Alkan, 2006, The Journal of experimental medicine.

Oligodeoxynucleotides Response Modifiers and PolyT a Combination of Imidazoquinoline Immune Cutting Edge : Activation of Murine TLR 8 by Binsfeld ,

J. Vasilakos, S. Alkan, Xiaohong X. Qiu, 2006 .

Synthetic TLR Agonists Reveal Functional Differences between Human TLR7 and TLR8

M. Tomai, R. Kedl, J. Vasilakos, 2005, The Journal of Immunology.

TLR8 Differences between Human TLR7 and Synthetic TLR Agonists Reveal Functional

M. Tomai, R. Kedl, J. Vasilakos, 2005 .

The role of B7 costimulation by murine acute myeloid leukemia in the generation and function of a CD8+ T-cell line with potent in vivo graft-versus-leukemia properties.

G. Gray, B. Blazar, P. Taylor, 1997, Blood.

Synthetic TLR Agonists Reveal Functional Differences between Human TLR7 and TLR8

M. Tomai, R. Kedl, J. Vasilakos, 2005, Journal of Immunology.

Interleukin-2 gene transfer into murine neuroblastoma decreases tumorigenicity and enhances systemic immunity causing regression of preestablished retroperitoneal tumors.

R. McIvor, B. Blazar, P. Orchard, 1994, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

Binding of Soluble Yeast β-Glucan to Human Neutrophils and Monocytes is Complement-Dependent

N. Bose, J. Vasilakos, A. Chan, 2013, Front. Immunol..

A randomized, open-label, multicenter, phase II study evaluating the efficacy and safety of BTH1677 (1,3–1,6 beta glucan; Imprime PGG) in combination with cetuximab and chemotherapy in patients with advanced non-small cell lung cancer

J. Marier, F. Schneller, M. Thomas, 2017, Investigational New Drugs.

Distinct indirect pathways govern human NK-cell activation by TLR-7 and TLR-8 agonists.

Jeffrey S. Miller, M. Tomai, J. Vasilakos, 2006, International immunology.

Imprime PGG Enhances Anti-Tumor Effects of Tumor-Targeting, Anti-Angiogenic, and Immune Checkpoint Inhibitor Antibodies

J. Graff, M. Uhlik, N. Bose, 2022, Frontiers in Oncology.

Immunoglobulin Restores Immune Responses to BTH1677 in Patients With Low Levels of Antibodies to Beta-glucan

N. Bose, A. Dudek, Xiaohong X. Qiu, 2020, AntiCancer Research.

Modulate Activation of TLR7 and TLR8 by Oligodeoxynucleotides Differentially

J. Battiste, J. Vasilakos, Xiaohong X. Qiu, 2013 .

a Combination of Imidazoquinoline Immune Cutting Edge: Activation of Murine TLR8 by

John P. Vasilakos, Sefik S. Alkan Keith, Keith B. Gorden, 2013 .

Oligodeoxynucleotides Differentially Modulate Activation of TLR7 and TLR8 by Imidazoquinolines

J. Battiste, J. Vasilakos, S. Alkan, 2006, The Journal of Immunology.

Cutting Edge: Activation of Murine TLR8 by a Combination of Imidazoquinoline Immune Response Modifiers and PolyT Oligodeoxynucleotides

John P. Vasilakos, J. Vasilakos, S. Alkan, 2006, The Journal of Immunology.

Imidazoquinolines Modulate Activation of TLR 7 and TLR 8 by Oligodeoxynucleotides Differentially

J. Battiste, J. Vasilakos, S. Alkan, 2006 .

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, Brian D. Kelly, 2016, Journal of Immunotherapy for Cancer.

Dependency on intercellular adhesion molecule recognition and local interleukin-2 provision in generation of an in vivo CD8+ T-cell immune response to murine myeloid leukemia.

P. Anderson, B. Blazar, P. Orchard, 1995, Blood.

Imprime PGG-Mediated Anti-Cancer Immune Activation Requires Immune Complex Formation

J. Graff, N. Bose, A. Chan, 2016, PloS one.

Immune Pharmacodynamic Responses of the Novel Cancer Immunotherapeutic Imprime PGG in Healthy Volunteers

J. Graff, M. Uhlik, Kathryn A. Fraser, 2019, The Journal of Immunology.

Abstract LB-129: Imprime PGG, a soluble yeast β-glucan PAMP, in combination with Pembrolizumab induces infiltration and activation of both innate and adaptive immune cells within tumor sites in melanoma and triple-negative breast cancer (TNBC) patients

J. Graff, M. Uhlik, B. Osterwalder, 2018, Immunology.

Abstract LB-089: Imprime PGG, a β-glucan PAMP (pathogen-associated molecular pattern), effectively elicits in vivo maturation of antigen presenting cells in mice and humans, suggesting potential synergy with checkpoint inhibitor therapy

J. Graff, Kathryn A. Fraser, N. Bose, 2016 .

B7-1 expression decreases tumorigenicity and induces partial systemic immunity to murine neuroblastoma deficient in major histocompatibility complex and costimulatory molecules.

G. Gray, B. Blazar, P. Orchard, 1995, Cancer gene therapy.

Abstract 5034: Imprime PGG decreases regulatory T cell suppression and enhances T cell proliferation and differentiation revealing additional mechanisms for its anti-tumor activity

Lindsay R. Wurst, K. Gorden, Ross B. Fulton, 2015 .

Endogenous anti-β-glucan antibodies as a potential predictive biomarker for clinical response to imprime PGG immunotherapy in non-small cell lung cancer (NSCLC) patients.

Michael Thomas, F. Schneller, D. McMurray, 2014 .

Abstract B019: Imprime PGG, a soluble β-glucan, binds to and activates dendritic cells resulting in enhanced T cell priming, expansion, and cytokine production

J. Graff, Michael E. Danielson, Kyle S. Michel, 2016 .

Abstract A160: Imprime PGG binds to neutrophils through complement, Fc, and dectin-1 receptors, priming these cells for enhanced ROS production and tumor cell cytotoxicity

J. Graff, A. Chan, Lindsay R. Wurst, 2016 .

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts

Amanda R. Campbell, F. Lund-Johansen, Yair Benita, 2016 .

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, David M. Schauder, 2016, Journal for ImmunoTherapy of Cancer.